Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines. In this study, forty patients in the chronic p...

Full description

Saved in:
Bibliographic Details
Main Authors: Silvia Catellani, Ivana Pierri, Marco Gobbi, Alessandro Poggi, Maria Raffaella Zocchi
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2011
Subjects:
R
Q
Online Access:https://doaj.org/article/43a888f74f0d45ed92183b04cada8d05
Tags: Add Tag
No Tags, Be the first to tag this record!